When Teva Pharmaceutical Industries Ltd. refocused R&D on key growth drivers last December, management said cancer programs would have to clear a high hurdle to justify investment. Research programs from Cancer Research Technology Ltd. targeting DNA damage and repair processes appear to be the first external programs to clear the bar.

Late last month, the partners announced a three-year deal to develop compounds against targets that CRT selects and validates from Cancer Research UK. CRT is the commercial arm of CRUK.